Skip to Main Content
For US Healthcare Professionals Only

Menu

Full Prescribing Information
References
Patient Site

Skip to Main Content
For US Healthcare Professionals Only

Why Nebulization
Efficacy & Safety
- MOA
- Efficacy Data
- Safety Profile
Dosing &
Administration
Access & Coverage
Resources

This site is intended for US healthcare professionals.

By clicking “continue” you acknowledge that you are a US healthcare professional.

CONTINUE

You are now leaving YUPELRIHCP.com,
a Viatris Inc. company website.

The information provided in YUPELRIHCP.com is intended only for healthcare professionals in the United States.

This site is intended for US healthcare professionals.

By clicking “continue,” you acknowledge that you are a US healthcare professional.

Something Went Wrong

Sorry, the page you were looking for could not be found.

You can return to the home page if you can't find what you're looking for.

Important Safety Information

Expand

Indication

YUPELRI^® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta₂-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

For additional information, please contact us at 1-800-395-3376.

Why Nebulization
Efficacy & Safety
Dosing &
Administration
Access & Coverage
Resources

YUPELRI and the Yupelri Logo are registered trademarks of Viatris Specialty LLC. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris Company. THERAVANCE BIOPHARMA^®, THERAVANCE^®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). PARI TREK and PARI LC SPRINT are registered trademarks of PARI GmbH.

© 2025 Viatris Inc. All Rights Reserved. US-REV-2024-00176 V2

Privacy Notice
Copyright and Legal Disclaimer
Cookie Notice
California Supplemental Disclosure
Contact us
Patient Website